CClinicalTrials.gg
TerminatedNCT00776087EuroEcoUpdated Jul 2, 2017

European Health Economic Trial on Home Monitoring in ICD and CRT-D Patients (EuroEco)

An interventional study of Home Monitoring provided by Biotronik ICD and CRT-D devices and No Home Monitoring in Ventricular Fibrillation, Tachycardia, Ventricular and Ventricular Flutter, sponsored by Biotronik SE & Co. KG. Terminated at 17 sites in 6 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-07-02.

Sponsored by Biotronik SE & Co. KG · Not applicable, Interventional, and Treatment

Why this study was terminated
it is unethical to continue a study with deactivation of HM in the control arm although a reduced risk of all-cause death has been shown in previous trials
Phase
Not applicable
Study type
Interventional
Enrollment
409
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

BIOTRONIK Home Monitoring (HM) service enables the doctors to safely follow up (FU) their ICD and CRT-D patients in a remote fashion, with fewer in-clinic consultations. This may result in a more efficient FU and cost-savings for the health care payer.

The EuroEco study:

  1. Outlines a new HM-based FU model for the ICD and CRT-D patients that combines in-clinic consultations and regular check ups of the patient/ICD/CRT-D data received through the HM service.
  2. Compares the direct costs for physicians and clinics for the HM-based FU of ICD and CRT-D patients versus the traditional FU.
  3. Compares the indicators of patients' safety between the two FU models.
Read the detailed description

The EuroEco is a prospective, international, randomized study aimed at assessing the economic effects of BIOTRONIK Home Monitoring (HM) technology as compared with traditional follow up (FU) of ICD and CRT-D patients from two perspectives: 1) the cost-effectiveness for the payer of health care, and 2) the economic impact on the physician, hospital and patient. The study outlines a new model for the FU of ICD-and CRT-D patients based on a combination of in-clinic consultations and regular check ups of the patient data received through the HM service.

About 312 patients with an indication for ICD therapy and 104 patients with an indication for de novo CRT-D implantation should be enrolled. All patients will be implanted with BIOTRONIK ICD or CRT-D devices from the Lumax families and randomized (1:1) to the traditional, or to HM-based FU model. Traditional FU will be performed according to the local clinical practice. Patients in the HM study arm will first undergo local clinical FU routine until the first in-clinic visit after patient discharge. Thereafter routine in-clinic FUs are scheduled at 12 and 24 months. Three HM data checks should be carried out during each 12-month interval, to assess the patient/ICD/CRT-D status remotely.

In both (HM and no HM) groups, additional in-hospital FU may be scheduled any time the patients reports symptoms which are presumed to be cardiovascular symptoms. In the HM group, additional in-clinic FU may also be scheduled as a result of specific HM findings.

The following FU-related activities were accounted for: in-clinic consultations, patients contact, discussion with colleague physician, nurse or technician and arranging in clinic consultation. In HM patients, two additional HM-related FU activities were taken into account: 1) checking the website of BIOTRONIK HM Service Center, and 2) checking HM-related emails and faxes (provided by BIOTRONIK HM Service Center)..

Several tools were made available to document the time that physicians, nurses and technicians spend with these FU activities without disrupting their clinical routine much:

  • designated case report forms
  • a web-based time measurements software.

A user manual for time measurements was handed out to physicians, nurses and technicians to recommend which tool should be used in which clinical situation. The average time per patient followed according to the traditional FU model and the average time per patient followed by the HM-based FU model will be calculated for each of the three health care professionals considered (physicians, nurses and technicians). The difference in costs between the traditional and the HM-based FU will be assessed for statistical significance.

This trial may provide data warranting a change in the guidelines for the use of ICD and CRT-D devices featuring HM function, in that HM may justify a prolongation of the time interval between statutory routine in-clinic FU visits. Coupled with the fact that the information provided by HM helps physicians to recognize some otherwise unsuspected needs for additional FU visits, this may ultimately result in better and more cost-effective health care for all parts involved (patients, providers and payers).

02

Conditions studied

  • Ventricular Fibrillation
  • Tachycardia, Ventricular
  • Ventricular Flutter

Keywords

  • Medical costs
  • Telemonitoring
  • Implantable cardioverter-defibrillator
03

In context

Tachycardia

623 studies on the registry are indexed under Tachycardia; 81 are open to participants now.

This study's enrollment of 409 is above the median of 64 across 379 interventional studies indexed under Tachycardia.

Browse Tachycardia studies →

Lead sponsor

Biotronik SE & Co. KG is the lead sponsor of 83 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

ICD Patient Population - Inclusion Criteria

  • Indication for 1-/2- chamber ICD implantation, including replacement indication
  • Patient is willing and able to comply with the clinical investigation plan and has provided written informed consent

ICD Patient Population - Exclusion Criteria

  • Patients with contraindication to ICD implantation
  • Patients with indication for cardiac resynchronization (CRT)
  • Minors and pregnant women
  • Patients participating in another study

CRT-D Patient Population - Inclusion Criteria

  • Patients with indication for de novo CRT-D implantation according to current guidelines
  • Patient is willing and able to comply with the clinical investigation plan and has provided written informed consent

CRT-D Patient Population - Exclusion Criteria

  • Patients who had a cardiac device implanted before (upgrade, device replacement)
  • Life expectancy less than 12 months
  • Planned heart transplantation
  • NYHA IV
  • Minors \< 18 years
  • Pregnant and breast-feeding women
  • Participation in another clinical study
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
409 participants (actual)

Study arms

  • Experimental
    1 = Home Monitoring

    Remote monitoring of ICD and CRT-D function and patient status

    Device: Home Monitoring provided by Biotronik ICD and CRT-D devices

  • Active comparator
    2 = No Home Monitoring

    Home Monitoring option is switched off

    Device: No Home Monitoring

Interventions

  • DeviceHome Monitoring provided by Biotronik ICD and CRT-D devices

    Remote monitoring of ICD and CRT-D function and patient status may result in more effective follow-up and increased patient safety

  • DeviceNo Home Monitoring

    Home Monitoring option is switched off (in the same kind of devices as used in the other study arm).

06

What researchers measure

Primary outcomes

  1. Euro spent to follow up ICD and CRT-D patients

    Time frame: 26 months

Secondary outcomes

  1. Average number of in-hospital follow-up visits per patient

    Time frame: 26 months

  2. Time to first in-hospital follow-up visit beyond the first post-implantation visit

    Time frame: 12 months

  3. Effective financial impact on hospitals / physicians

    Time frame: 26 months

  4. Proportion of in-hospital consultations with relevant findings (i.e. necessitating changes in medical therapy, device programming or re-hospitalisations/ interventions)

    Time frame: 26 months

  5. Proportion of patients with HM-triggered interventions that, without remote monitoring, would have first been discovered at a subsequent scheduled follow-up

    Time frame: 26 months

  6. Incidence of inappropriate ICD shocks

    Time frame: 26 months

  7. Changes in quality-of-life (SF-36) from baseline to the 12- and to 24-month follow-up visits

    Time frame: 26 months

07

Study locations

17 sites
  • Heart Rhythm Management Institute, Free University of Brussels
    Brussels, Belgium
  • Ziekenhuis Oost Limburg, Campus St. Jan
    Genk, Belgium
  • Jessa Ziekenhuis (Campus Virga Jesse)
    Hasselt, Belgium
  • ZU Gasthuisberg
    Leuven, Belgium
  • University of Oulu
    Oulu, 90014, Finland
  • Helios Klinikum Aue
    Aue, 08280, Germany
  • Charité Berlin Campus Mitte
    Berlin, 10117, Germany
  • Städt. Klinikum St. Georg gGmbH
    Leipzig, 04129, Germany
  • Herzzentrum Leipzig, Abteilung Rhythmologie
    Leipzig, Germany
  • Leiden Universitair Medisch Centrum
    Leiden, 2333, Netherlands
  • Hospital Universitario La Paz
    La Paz, Spain
  • Hospital Universitario Puerta de Hierro Majadahonda
    Madrid, Spain
  • Hospital Ntra.Sra.de la Candelaria
    Tenerife, Spain
  • Arrythmia Unit, Complejo Hospitalario de Vigo (Hospital Xeral)
    Vigo, Spain
  • Cardiology, Aberdeen Royal Infirmary
    Aberdeen, United Kingdom
  • Cardiology, St. Peters Hospital/St. George's
    Chertsey, United Kingdom
  • Cardiology; Raigmore Hospital
    Inverness, United Kingdom
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 2, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00776087
Lead sponsor
Biotronik SE & Co. KG
Responsible party
Sponsor
First posted
Oct 20, 2008
Start date
Oct 17, 2008
Primary completion
Jul 21, 2016
Completion
Oct 27, 2016
Last update
Jul 2, 2017

Study contacts

Hein Heidbüchel, Prof. Dr.
study chair · ZU Gasthuisberg, Leuven, Belgium

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion